0001209191-24-000175.txt : 20240102 0001209191-24-000175.hdr.sgml : 20240102 20240102165849 ACCESSION NUMBER: 0001209191-24-000175 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231228 FILED AS OF DATE: 20240102 DATE AS OF CHANGE: 20240102 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Larson Tina Marriott CENTRAL INDEX KEY: 0001856414 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40323 FILM NUMBER: 24503285 MAIL ADDRESS: STREET 1: C/O RECURSION PHARMACEUTICALS STREET 2: 41 S. RIO GRANDE STREET CITY: SALT LAKE CITY STATE: UT ZIP: 84101 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: RECURSION PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001601830 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 464099738 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 41S RIO GRANDE STREET CITY: SALT LAKE CITY STATE: UT ZIP: 84101 BUSINESS PHONE: (385) 269-0203 MAIL ADDRESS: STREET 1: 41S RIO GRANDE STREET CITY: SALT LAKE CITY STATE: UT ZIP: 84101 FORMER COMPANY: FORMER CONFORMED NAME: Recursion Pharmaceuticals, LLC DATE OF NAME CHANGE: 20140305 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-12-28 0 0001601830 RECURSION PHARMACEUTICALS, INC. RXRX 0001856414 Larson Tina Marriott 41 S. RIO GRANDE STREET SALT LAKE CITY UT 84101 0 1 0 0 President and COO 1 Class A Common Stock 2023-12-28 4 M 0 8000 1.06 A 422548 D Class A Common Stock 2023-12-28 4 S 0 8000 10.5817 D 414548 D Stock Option (Right to Buy) 8.55 2033-02-01 Class A Common Stock 0 434122 D Stock Option (Right to Buy) 1.06 2023-12-28 4 M 0 8000 0.00 D 2028-07-22 Class A Common Stock 8000 512000 D Stock Option (Right to Buy) 11.40 2032-02-04 Class A Common Stock 0 159226 D Stock Option (Right to Buy) 11.40 2022-02-04 2032-02-04 Class A Common Stock 0 4784 D Stock Option (Right to Buy) 2.48 2030-12-30 Class A Common Stock 0 150000 D Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023. Includes 1,144 shares purchased pursuant to the Issuer's Employee Stock Purchase Plan on November 20, 2023. The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $10.34 to $10.75 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. One forty-eighth (1/48th) of the shares subject to the award shall vest one month after December 31, 2020, or the Monthly Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Monthly Vesting Commencement Date. /s/ Jonathan Golightly, attorney-in-fact 2024-01-02